VaxEquity Ltd

👥 8 employees💰 Last funded Jun 2020
Biotechnology Research🌐 vaxequity.com
Website LinkedIn
VaxEquity is a biotechnology company amplifying the impact of RNA vaccines and therapeutics, through using its next generation self-amplifying RNA (saRNA) platform. The Company uses saRNA to provide greatly enhanced protein expression, combining better tolerability with slower release and thermostability. VaxEquity is pioneering a next generation approach by modifying its saRNA to modulate the immune response and thereby overcoming current limitations. The flexibility of the Company’s platform ensures that its broad pipeline of assets can be designed, developed, and manufactured rapidly and at scale. VaxEquity was founded in 2020 by Professor Robin Shattock, the Head of Immunology of Infection at Imperial College London and is led by a world class team who are pioneers in the field of RNA.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in VaxEquity Ltd?
VaxEquity Ltd has 1 investors on record on gritt.io.
When did VaxEquity Ltd last raise funding?
The most recent investment in VaxEquity Ltd recorded on gritt.io was in June 2020.
What industry is VaxEquity Ltd in?
VaxEquity Ltd operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.